

<h3>Bibliografía</h3>

    <ol>
        <li>Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. 2015.</li>
        <li>Lutz J, Weinmann-Menke J. Bleeding in uremia. In: Management of Bleeding Patients; 2016 p. 151-7. DOI:10.1007/978-3-319-30726-8_16.</li>
        <li>Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3(3):138-53.</li>
        <li>Ma TK-W, Chow KM, Kwan BC-H, Leung CB, Szeto CC, Li PK-T. Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. Nephrology 2017;22(4):316-21.</li>
        <li>Lamba G, Kaur H, Adapa S, Shah D, Malhotra BK, Rafiyath SM, et al. Use of conjugated estrogens in life-threatening gastrointestinal bleeding in hemodialysis patients- A review. Clin Appl Thromb 2013;19(3):334-7.</li>
        <li>Cheung KL, Zakai NA, Folsom AR, Kurella Tamura M, Peralta CA, et al. Measures of Kidney Disease and the Risk of Venous Thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2017;70(2):182-90.</li>
        <li>Rattazzi M, Villalta S, de Lucchi L, Sponchiado A, Galliazzo S, Faggin E, et al. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence. Thromb Res 2017;160:32-7.</li>
        <li>Dekkers IA, de Mutsert R, de Vries APJ, Rosendaal FR, Cannegieter SC, Jukema JW, et al. Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. J Thromb Haemost 2018;16:519-28.</li>
        <li>Yang K, Du C, Wang X, Li F, Xu Y, Wang S, et al. Uremic solute indoxyl sulfate-induced platelet hyperactivity contributes to CKD-associated thrombosis in mice. Blood 2017;11;129(19):2667-79.</li>
        <li>Stępniewska J, Dołęgowska B C-HE. The activity of antioxidant enzymes in blood platelets in different types of renal replacement therapy: a cross-sectional study. Int Urol Nephrol 2016;48(4):593-9.</li>
        <li>Mörtberg J, Blombäck M, Wallén H, He S, Jacobson SH, Spaak J. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease. Blood Coagul Fibrinolysis 2016;27(4):401-7.</li> 
        <li>Cho J, Jun KW, Kim MH, Hwang JK, Moon IS, Kim J Il. Coagulation profile in patients with chronic kidney disease before and after kidney transplantation: A retrospective cohort study. Clin Transplant 2017;31(9). DOI:10.1111/ctr.13051.</li>
        <li>Kopel T, Kaufman JS, Hamburg N, Sampalis JS, Vita JA, Dember LM. Endothelium-dependent and -independent vascular function in advanced chronic kidney disease. Clin J Am Soc Nephrol 2017;12(10):1588-94.</li>
        <li>Helmke A, Vietinghoff S von. Extracellular vesicles as mediators of vascular inflammation in kidney disease. World J Nephrol 2016;5(2):125.</li>
        <li>Dobry AS, Ko LN, St John J, Sloan JM, Nigwekar S, Kroshinsky D. Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease. JAMA Dermatology Dec 2018;154:182-7.</li>
        <li>Ismail G, Mircescu G, Ditoiu AV, Tacu BD, Jurubita R, Harza M. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: Focus on haemostasis-related parameters. Int Urol Nephrol 2014;46(4):787-92.</li> 
        <li>Salmela A, Ekstrand A, Joutsi-Korhonen L, Raisanen-Sokolowski A, Lassila. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 2015;30(Suppl 1):53-9.</li>
        <li>Berden AE, Nolan SL, Morris HL, Bertina RM, Erasmus DD, Hagen EC, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol 2010;21(12):2169-79.</li>
        <li>Bilha SC, Burlacu A Siriopol D, Voroneanu L CA. Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update. Cerebrovasc Dis 2018;45(1-2):33-41.</li>
        <li>Roldán V, Marín F, Manzano-Fernández S, Fernández H, Gallego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109(5):956-60.</li>
        <li>Béland S, Vallin P, Désy O, Lévesque E, de Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. J Thromb Haemost 2017;15(5):1020-31.</li>
        <li>Bijkerk R, Florijn BW, Khairoun M, Duijs JMGJ, Ocak G, de Vries APJ, et al. Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury. Transplant Direct 2017;3(7):e174.</li>
        <li>Baas MC, Gerdes VEA, Ten Berge IJM, Heutinck KM, Florquin S, Meijers JCM, et al. Treatment with everolimus is associated with a procoagulant state. Thromb Res 2013;132(2):307-11.</li>
        <li>Brahmbhatt A, Misra S. The Biology of Hemodialysis Vascular Access Failure. Semin Intervent Radiol 2016;33(1):15-20.</li> 
        <li>Burlacu A, Genovesi S, Goldsmith D, Rossignol P, Ortiz A, Kalra PA, et al. Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal. Pharmacol Res 2018;129:535-43.</li>
        <li>Franchi F, Rollini F, Angiolillo DJ. Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(6)e002760.</li>
        <li>Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, et al. Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemost 2016;14(2):375-80. 
        <li>Bai Y, Chen H, Yang Y, Li L, Liu XY, Shi XB, et al. Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review. Thromb Res 2016;137:46-52.</li>
        <li>Sharif-Askari S. Anticoagulation Therapy in Patients with Chronic Kidney Disease. Adv Exp Med Biol 2017;906:101-14.</li>
        <li>Leizorovicz A, Siguret V, Mottier D. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep® in Renal Insufficiency Study (IRIS). Thromb Res 2011;128(1):27-34.</li>
        <li>Park D, Southern W, Calvo M, Kushnir M, Solorzano C, Sinnet M, et al. Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. J Gen Intern Med 2016;31(2):182-7.</li> 
        <li>Li B, Lu D, Chen Y, Zhao M, Zuo L. Unfractionated heparin promotes osteoclast formation in vitro by inhibiting osteoprotegerin activity. Int J Mol Sci 2016;17(4):613.</li>
        <li>Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015;66(4):677-88.</li>
        <li>Fusaro M, D’Alessandro C, Noale M, et al. Low vitamin K1 intake in haemodialysis patients. Clin Nutr. 2017;36(2):601-7.</li>
        <li>Han KH, O’Neill WC. Increased peripheral arterial calcification in patients receiving warfarin. J Am Heart Assoc 2016;5(1):1-8.</li> 
        <li>Lobos-Bejarano JM, Castellanos Rodríguez A, Barrios V, Escobar C, Polo-García J, del Castillo-Rodríguez JC, et al. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract 2017;71(9). DOI:10.1111/ijcp.12974.</li>
        <li>Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017;6(3). DOI:10.1161/JAHA.116.004925.</li>
        <li>Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20(10):2223-33.</li> 
        <li>Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: Evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016;13(14):14.</li>
        <li>Albrecht D. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. Thromb Haemost.2017;117(11):2026-33.</li>
        <li>Qamar A, Bhatt DL. Stroke Prevention in Atrial Fibrillation in Patients with Chronic Kidney Disease. Circulation 2016;133(15):1512-5.</li>
        <li>Genovesi S, Carrero JJ. International Normalized Ratio Control in Patients With Atrial Fibrillation and CKD. Am J Kidney Dis 2017;69:863.</li>
        <li>Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane database Syst Rev 2017;11:CD011373.</li>
        <li>Schwartz JB. Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. J Am Geriatr Soc 2016;64(10):1996-2002.</li>
        <li>Di Lullo L, Ronco C, Cozzolino M, Russo D, Russo L, Di Iorio B, et al. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res 2017;155:38-47.</li> 
        <li>Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations. Int J Nephrol Renovasc Dis 2017;10:135-43.</li>
        <li>Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int J Cardiol 2017;231:162-9.</li> 
        <li>Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 2. Eur Heart J 2017;38(12):860-8.</li> 
        <li>Sciascia S, Radin M, Schreiber K, Fenoglio R, Baldovino S, Roccatello D. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med 2017;12(8):1101-8.</li>
        <li>Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, et al. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Thromb Haemost 2017;117(11):2045-52.</li>
        <li>Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and kidney disease: A bad combination. Clin J Am Soc Nephrol 2013;8(9):1591-7.</li>
        <li>Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major Bleeding and Hemorrhagic Stroke with Direct Oral Anticoagulants in Patients with Renal Failure Systematic Review and Meta-Analysis of Randomized Trials. Chest 2016;149(6):1516-24.</li>
        <li>Wang X, Tirucherai G, Marbury TC, Chang M, Zhang D, Song Y, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56(5):628-36.</li>
        <li>Pelliccia F, Rosanio S, Marazzi G, Poggi S, Tanzilli A, Greco C, et al. Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. Int J Cardiol 2016;225:77-81.</li>
        <li>Büller HR, Décousus H, Grosso M, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-15.</li>
        <li>Arepally GM. Heparin-induced thrombocytopenia. Blood 2017;129(21):2864-72.</li>
        <li>Job H, Ingrid J, Tivadar F, Lukas P. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 2005;19(1):65-9.</li>
        <li>Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost 2016;14(3):461-7.</li>
    </ol>